Becker's ASC

Beating CRC, one test at a time — Exact Sciences’ Mark Stenhouse stumps for Cologuard

Mark Stenhouse left his executive role at AbbVie to join Exact Sciences because he felt the company was fighting a worthy battle: preventing colorectal cancer. Mr. Stenhouse, now Exact Science’s ...
The American Journal of Managed Care

CRC Screening Should Be Continued in Older Patients Who Smoke, Have History of Disease

A study found significant incidence of advanced neoplasia in patients who had a colonoscopy to screen for colorectal cancer (CRC) when aged more than 75 years. The incidence of CRC is known to ...
Healio

Offering a blood test as a secondary option boosts CRC screening by nearly twofold

Offering a blood test as a secondary option in individuals who previously declined colonoscopy or FIT increased CRC screening by 7.5%. There was no decrease in uptake of first-line screening options.
Medscape

FDA OKs Next-Gen Cologuard Test for CRC Screening

The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...
Hosted on MSN

Exact Sciences to acquire US rights for Freenome’s blood-based CRC test

Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based colorectal cancer (CRC) screening test in the US. Exact ...